Get all premium features to the best stock analysis tool

SOPHiA GENETICS Reports Fourth Quarter and Full Year 2025 Results

BOSTON and ROLLE, Switzerland, March 3, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the fourth quarter and fiscal year ended December 31, 2025. Fourth Quarter 2025 Financial Results Revenue was $21.7 million, up 22% year-over-year Gross margin was 67.7% on a reported basis and 73.9% on an adjusted basis, compared to 68.2% reported and 74.2% adjusted in the prior year period IFRS net loss was $19.2 million, an increase of 27% year-over-year; Adjusted EBITDA loss was $9.9 million, an increase of 9% year-over-year Full Year 2025 Financial Results Revenue was $77.3 million, up 19% year-over-year Gross margin was 67.4% on a reported basis and 74.2% on an adjusted basis, compared to 67.4% reported and 72.8% adjusted in the prior year period IFRS net loss was $79.0 million, an increase of 26% year-over-year; Adjusted EBITDA loss was $41.5 million, an increase of 3% year-over-year "We finished 2025 strong, with Q4 revenue growing 22% and full-year revenue increasing 19% year-over-year, as our growth momentum continues to accelerate," said Jurgi Camblong, Chief Executive Officer and co-founder of SOPHiA GENETICS.

SOPHiA GENETICS Announces Major Expansion in the United States with the Signing of Two Major Integrated Health Systems

BOSTON and ROLLE, Switzerland, Feb. 10, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, today announced the addition of two of the largest U.S. healthcare systems to its network. The two new institutions, which collectively analyze millions of genetic samples annually, include one of the leading nonprofit, multi-region integrated healthcare systems in the U.S. and a top 10 U.S. health system laboratory.

SOPHiA GENETICS Provides Preliminary Fourth Quarter and Full Year 2025 Financial Results, Initiates 2026 Guidance, and Announces Executive Transition Plan

The Company finishes 2025 with strong Q4 performance, expects 20-22% revenue growth in 2026, and promotes Ross Muken to CEO BOSTON and ROLLE, Switzerland, Jan. 12, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today provided preliminary unaudited financial results for the fourth quarter and full year 2025, initiated its financial outlook for 2026, and announced an executive transition plan, including the promotion of Ross Muken to Chief Executive Officer (CEO), effective July 1, 2026, and the transition of co-Founder Jurgi Camblong to Executive Chairman. Fourth Quarter 2025 Preliminary Unaudited Financial Results Revenue of at least $21 million, representing an increase of approximately 20% year-over-year Performed over 105,000 analyses on SOPHiA DDM™ in the fourth quarter, representing 16% year-over-year growth Full Year 2025 Preliminary Unaudited Financial Results Revenue of approximately $77 million, representing an increase of approximately 18% year-over-year Performed over 391,000 analyses on SOPHiA DDM™ in 2025, a new company record "2025 was a tremendous year for SOPHiA GENETICS as we reaccelerated revenue growth and materially exceeded our new business bookings target, setting the stage for robust future growth," said Jurgi Camblong, Chief Executive Officer of SOPHiA GENETICS.

SOPHiA GENETICS and MD Anderson Announce Strategic Collaboration to Accelerate AI-Driven Precision Oncology

BOSTON and HOUSTON, Jan. 7, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration that unites SOPHiA GENETICS' AI-powered analytics with MD Anderson's clinical and scientific expertise to accelerate data-driven cancer care through new tools that can accurately analyze, interpret and translate diagnostic results into clinical practice. As part of the collaboration, MD Anderson and SOPHiA GENETICS are launching a series of research and development programs and co-developing an advanced next-generation sequencing oncology test.